The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package
Thunyarat Anothaisintawee,1,2 Pattara Leelahavarong,1 Tanapat Ratanapakorn,3 Yot Teerawattananon11Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand; 2Family Medicine Department and Section of Clinical Epidemiology and Biostatistics, Ramathibodi Ho...
Saved in:
Main Authors: | Anothaisintawee T (Author), Leelahavarong P (Author), Ratanapakorn T (Author), Teerawattananon Y (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2012-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The greatest happiness of the greatest number? Policy actors' perspectives on the limits of economic evaluation as a tool for informing health care coverage decisions in Thailand
by: Russell Steve, et al.
Published: (2008) -
Intravitreal Bevacizumab Injection Effect in Exudative Age Related Macular Degeneration
by: Gholamhossein Yaghoobi, et al.
Published: (2016) -
Defining the Benefit Package of Thailand Universal Coverage Scheme: From Pragmatism to Sophistication
by: Viroj Tangcharoensathien, et al.
Published: (2020) -
Improvement of Diabetic Macular Edema in the Fellow Eye After Monocular Intravitreal Bevacizumab Injection
by: Hamidreza Torabi
Published: (2017) -
Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration
by: Gebran Khneizer, et al.
Published: (2017)